Virtu Financial’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Virtu Financial’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$82K	Buy	+16,138	New	+$85.4K	0.01%	1122
2019 Q2	–	Sell	-17,101	Closed	-$79K	–	2044
2019 Q1	$79K	Buy	+17,101	New	+$77.4K	﹤0.01%	1155
2018 Q4	–	Sell	-52,182	Closed	-$327K	–	2169
2018 Q3	$327K	Buy	+52,182	New	+$401K	0.02%	810
2018 Q2	–	Sell	-48,342	Closed	-$361K	–	2720
2018 Q1	$361K	Buy	+48,342	New	+$321K	0.02%	906

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial's PGNX Position: Q4 2019 in Review

Virtu Financial opened a new position in Progenics Pharmaceuticals Inc (PGNX) in Q4 2019: 16,138 shares worth $82K. The stake represents 0.01% of the portfolio and ranks #1122 among its holdings. This is a return to the name: Virtu Financial previously reported a position in PGNX as recently as Q1 2019.

Virtu Financial first reported a position in PGNX in Q1 2018 and has held it in 4 quarters since. The position peaked at $361K in Q1 2018. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

Virtu Financial held 16,138 shares of Progenics Pharmaceuticals Inc worth $82K as of Q4 2019.
Progenics Pharmaceuticals Inc was a new Virtu Financial position in Q4 2019.
Progenics Pharmaceuticals Inc made up 0.01% of Virtu Financial's portfolio in Q4 2019, its #1122 holding.
Virtu Financial first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and has held it in 4 quarters since.
Virtu Financial's Progenics Pharmaceuticals Inc position peaked at $361K in Q1 2018.
128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Virtu Financial's 13F filing for Q4 2019, filed 4 Feb 2020.